Minra Therapeutics Appoints Clay Siegall to Its Board

Renowned bio technologist Clay Siegall, has been appointed to the board of Minra Therapeutics. Dr. Siegall will serve the board as an autonomous director. Founded in 2007, the Texas-based company focuses on the advancement of microRNA in the field of biotechnology. For the past few years, it has also been dedicated to cancer research, an area that Dr. Siegall is well-versed in. his experience and expertise will therefore, boost Minra’s efforts.

Since its formation, Minea Therapeutics has gained market dominance due to its ability to develop products that address the needs of the market. The firm boosts the services of renowned researchers, who play a significant role in the advancement of top-notch products. The dedication that it has towards innovation has seen it come up with products that have fully been integrated into cancer therapies offered throughout the world. With the addition of Dr. Siegall, Minra Therapeutics boasts an experienced and competent board, which will ultimately guide it towards greater heights.

Important Notes about ClaySiegall

Dr. Siegall is one of the most prolific biotechnologists in the United States. His name is synonymous with Seattle Genetics, a biotechnology firm that he co-founded in 1998 with the aim of advancing cheaper, advanced, and more pragmatic cancer therapies. Siegall’s proactive approach to research and entrepreneurship has seen him become the company’s bedrock. He not only leads its business operations, but also its scientific research teams. Therapies that have emerged from the company’s remarkable production line are currently used to treat cancer in over 70 countries.

Seattle Genetics was catapulted into the limelight following the advancement of world-renowned cancer therapy, ADCETRIS, which is its top product. The firm has similarly produced a number of therapies, which are available in different parts of the world. However, its ascent to the top of the biotechnology world has been buoyed by Dr. Siegall’s extensive networks, which have enabled him to seek funding from various sources. Over 675 million dollars has been channeled towards research, and the construction of the ultra-modern facility in Washington, which houses the company. Dr. Siegall studied at George Washington University, and the University of Maryland. He is a board director of several notable pharmaceutical companies.